MedTrace Logo

Efficacy of Faviprevir in COVID-19 Treatment

NCT04351295 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2021-11-01

No results posted yet for this study

Summary

Faviprevir in COVID-19 treatment

Conditions

Interventions

DRUG

Favipiravir

Favipiravir

DRUG

Chloroquine

chloroquine oral tablets

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • sherief Abd-Elsalam, Ass. Prof. · Tanta University - Faculty of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-20
Primary Completion
2020-09-28
Completion
2020-09-28

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04351295 on ClinicalTrials.gov